Novo Nordisk is slashing 250 US jobs in an ongoing reorganization of the business.
MedWatch reported that the pharma company is whacking 100 back office jobs while eliminating another 150 “educators” involved in its diabetes business.
The latest cutbacks follow closely on a plan to restructure its $1 billion R&D organization. Just days ago the company outlined a plan to ax 400 R&D jobs in China and Denmark as they set up 4 new research groups in Indianapolis, the UK and their home base in Denmark. The unit in Indianapolis, home town to rival Eli Lilly, will focus on diabetes and obesity, a major theme at Novo while the Oxford team concentrates on cardio-metabolic research.
Danish media have been following Novo’s moves closely, reporting over the summer that their plans could affect thousands of jobs in the company.
Novo spokesperson Mike Rulis told MedWatch that the money the company is saving will go into areas of opportunity, like increased promotional support for Ozempic. The moves, he added, are being driven by a new pricing environment in the US, where discounts for major payers are standard.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,600+ biopharma pros who read Endpoints News by email every day.Free Subscription